Read by QxMD icon Read

European Heart Journal

Sarah Costantino, Alexander Akhmedov, Giovanni Melina, Shafeeq A Mohammed, Alaa Othman, Samuele Ambrosini, Winandus J Wijnen, Lidia Sada, Giuseppino M Ciavarella, Luca Liberale, Felix C Tanner, Christian M Matter, Thorsten Hornemann, Massimo Volpe, Fatima Mechta-Grigoriou, Giovanni G Camici, Riccardo Sinatra, Thomas F Lüscher, Francesco Paneni
Aims: Metabolic cardiomyopathy (MC)-characterized by intra-myocardial triglyceride (TG) accumulation and lipotoxic damage-is an emerging cause of heart failure in obese patients. Yet, its mechanisms remain poorly understood. The Activator Protein 1 (AP-1) member JunD was recently identified as a key modulator of hepatic lipid metabolism in obese mice. The present study investigates the role of JunD in obesity-induced MC. Methods and results: JunD transcriptional activity was increased in hearts from diet-induced obese (DIO) mice and was associated with myocardial TG accumulation and left ventricular (LV) dysfunction...
January 9, 2019: European Heart Journal
Jeffrey B Geske, Bernard J Gersh
No abstract text is available yet for this article.
January 9, 2019: European Heart Journal
Gijs F N Berkelmans, Soffia Gudbjörnsdottir, Frank L J Visseren, Sarah H Wild, Stefan Franzen, John Chalmers, Barry R Davis, Neil R Poulter, Annemieke M Spijkerman, Mark Woodward, Sara L Pressel, Ajay K Gupta, Yvonne T van der Schouw, Ann-Marie Svensson, Yolanda van der Graaf, Stephanie H Read, Bjorn Eliasson, Jannick A N Dorresteijn
Aims: Although group-level effectiveness of lipid, blood pressure, glucose, and aspirin treatment for prevention of cardiovascular disease (CVD) has been proven by trials, important differences in absolute effectiveness exist between individuals. We aim to develop and validate a prediction tool for individualizing lifelong CVD prevention in people with Type 2 diabetes mellitus (T2DM) predicting life-years gained without myocardial infarction or stroke. Methods and results: We developed and validated the Diabetes Lifetime-perspective prediction (DIAL) model, consisting of two complementary competing risk adjusted Cox proportional hazards functions using data from people with T2DM registered in the Swedish National Diabetes Registry (n = 389 366)...
January 9, 2019: European Heart Journal
Giuseppe Boriani, Christian T Ruff, Julia F Kuder, Minggao Shi, Hans J Lanz, Howard Rutman, Michele F Mercuri, Elliott M Antman, Eugene Braunwald, Robert P Giugliano
Aims: To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). Methods and results: In the ENGAGE AF-TIMI 48 trial, patients with AF were randomized to warfarin (international normalized ratio 2.0-3.0) or edoxaban. The cohort (N = 21 028) included patients across BMI categories (kg/m2): underweight (<18.5) in 0.8%, normal (18.5 to <25) in 21.4%, overweight (25 to <30) in 37.6%, moderately obese (30 to <35) in 24...
January 8, 2019: European Heart Journal
Ernesto L Schiffrin
No abstract text is available yet for this article.
January 8, 2019: European Heart Journal
Winnie Chua, Yanish Purmah, Victor R Cardoso, Georgios V Gkoutos, Samantha P Tull, Georgiana Neculau, Mark R Thomas, Dipak Kotecha, Gregory Y H Lip, Paulus Kirchhof, Larissa Fabritz
Aims: Undetected atrial fibrillation (AF) is a major health concern. Blood biomarkers associated with AF could simplify patient selection for screening and further inform ongoing research towards stratified prevention and treatment of AF. Methods and results: Forty common cardiovascular biomarkers were quantified in 638 consecutive patients referred to hospital [mean ± standard deviation age 70 ± 12 years, 398 (62%) male, 294 (46%) with AF] with known AF or ≥2 CHA2DS2-VASc risk factors...
January 7, 2019: European Heart Journal
Anne Langsted, Pia R Kamstrup, Børge G Nordestgaard
Aims: Several lipoprotein(a)-lowering therapies are currently being developed with the long-term goal of reducing cardiovascular disease and mortality; however, the relationship between lipoprotein(a) and mortality is unclear. We tested the hypothesis that lipoprotein(a) levels are associated with risk of mortality. Methods and results: We studied individuals from two prospective studies of the Danish general population, of which 69 764 had information on lipoprotein(a) concentrations, 98 810 on LPA kringle-IV type 2 (KIV-2) number of repeats, and 119 094 on LPA rs10455872 genotype...
January 4, 2019: European Heart Journal
Tae-Hoon Kim, Pil-Sung Yang, Hee Tae Yu, Eunsun Jang, Hyejung Shin, Ha Yan Kim, Jae-Sun Uhm, Jong-Youn Kim, Jung-Hoon Sung, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung, Gregory Y H Lip
Aims: There are a paucity of data on the association of duration of hypertension and blood pressure (BP) level with risk of ischaemic stroke in patients with atrial fibrillation (AF). Our objective was to investigate the association between duration of hypertension and secondly, BP levels with risk of ischaemic stroke among patients with AF. Methods and results: A total of 246 459 oral anticoagulant-naïve non-valvular AF patients were enrolled from Korea National Health Insurance Service (NHIS) database (2005-2015)...
January 4, 2019: European Heart Journal
Filippo Crea, Cathleen Noel Bairey Merz, John F Beltrame, Colin Berry, Paolo G Camici, Juan Carlos Kaski, Peter Ong, Carl J Pepine, Udo Sechtem, Hiroaki Shimokawa
Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect about 20-40% of patients during short-medium-term follow-up. This appears to be true even when PCI is 'optimized' using physiology-guided approaches and drug-eluting stents. Importantly, persistent or recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be almost two-fold higher among patients with persistent or recurrent angina post-PCI vs. those who become symptom-free...
January 4, 2019: European Heart Journal
Bernard D Prendergast, Helmut Baumgartner, Victoria Delgado, Olivier Gérard, Michael Haude, Anders Himmelmann, Bernard Iung, Matthew Leafstedt, Jasmine Lennartz, Francesco Maisano, Elena Andreassi Marinelli, Thomas Modine, Markus Mueller, Simon R Redwood, Olaf Rörick, Cherif Sahyoun, Erika Saillant, Lars Søndergaard, Martin Thoenes, Karen Thomitzek, Marion Tschernich, Alec Vahanian, Olaf Wendler, Evelyn Julia Zemke, Jeroen J Bax
Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups...
January 4, 2019: European Heart Journal
Michael Böhm, Felix Mahfoud, Raymond R Townsend, David E Kandzari, Stuart Pocock, Christian Ukena, Michael A Weber, Satoshi Hoshide, Manesh Patel, Crystal C Tyson, Joachim Weil, Tolga Agdirlioglu, Martin Fahy, Kazuomo Kario
Aims: The randomized sham-controlled SPYRAL HTN-OFF MED trial demonstrated that renal denervation (RDN) using a multi-electrode catheter lowers ambulatory blood pressure (BP) in non-medicated hypertensive patients. The current report describes the effects of RDN on heart rate (HR) in this population. Methods and results: Patients were enrolled with an office systolic BP (SBP) of ≥150 mmHg and <180 mmHg, office diastolic BP (DBP) of ≥90 mmHg, and a mean ambulatory SBP of ≥140 mmHg and <170 mmHg...
January 4, 2019: European Heart Journal
Thomas M Gorter, Dirk J van Veldhuisen, Adriaan A Voors
No abstract text is available yet for this article.
January 4, 2019: European Heart Journal
Ziliang Ye, Haili Lu, Qiang Su, Manyun Long, Lang Li
Aims: Whether a loading dose of atorvastatin (80 mg) can reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) remains controversial. Therefore, we performed this meta-analysis. Methods and results: Randomized controlled trials (RCT) comparing a loading dose of atorvastatin to a control in patients with ACS who underwent PCI were identified through searches of medical literature databases. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the primary endpoint...
January 3, 2019: European Heart Journal
Tze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Jo-Nan Liao, Fa-Po Chung, Tzeng-Ji Chen, Shih-Ann Chen
Aims: The stroke risk of patients with atrial fibrillation (AF) is not static, since AF patients get older and accumulate more comorbidities after AF is diagnosed. Therefore, the stroke risk of AF patients given certain comorbidities in different age strata should ideally be analysed using an assessment which considers incident comorbidities and the actual age when ischaemic stroke occurred. The goal of the present study is to report the age treatment thresholds for the use of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients without or with only one comorbidity of the CHA2DS2-VASc score, based on an 'ideal method' of stroke risk assessments...
January 2, 2019: European Heart Journal
Yusuke Yoshikawa, Takeshi Kimura
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Mohamed Abdel-Wahab, Holger Thiele
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Victor Aboyans, Mislav Vrsalovic, Juraj Madaric, Lucia Mazzolai, Marco De Carlo
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Natzi Sakalihasan, Jean-Olivier Defraigne, Martin Moïse, Christoph A Nienaber
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Josef Kautzner, Hugh Calkins, Jan Steffel
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Wojciech Wojakowski, Helmut Baumgartner
No abstract text is available yet for this article.
January 2, 2019: European Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"